
Phase II randomized trialProstate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Â Gy or two fractions of
Keywords: HDR; Monotherapy; Randomized Trial; EPIC; Toxicity;